Abstract:The landscape of cancer treatment has undergone a significant transformation with the introduction of Immune Checkpoint Inhibitors (ICIs). Patients undergoing these treatments often report prolonged clinical and radiological responses, albeit with a potential risk of developing immune-related adverse events (irAEs). Here, we reviewed and discussed the mechanisms of action of ICIs and their pivotal role in regulating the immune system to enhance the anti-tumor immune response. We scrutinized the intricate pathogenic mechanisms responsible for irAEs, arising from the evasion of self-tolerance checkpoints due to drug-induced immune modulation. We also summarized the main clinical manifestations due to irAEs categorized by organ types, detailing their incidence and associated risk factors. The occurrence of irAEs is more frequent when ICIs are combined; with neurological, cardiovascular, hematological, and rheumatic irAEs more commonly linked to PD1/PD-L1 inhibitors and cutaneous and gastrointestinal irAEs more prevalent with CTLA4 inhibitors. Due to the often-nonspecific signs and symptoms, the diagnosis of irAEs (especially for those rare ones) can be challenging. The differential with primary autoimmune disorders becomes sometimes intricate, given the clinical and pathophysiological similarities. In conclusion, considering the escalating use of ICIs, this area of research necessitates additional clinical studies and practical insights, especially the development of biomarkers for predicting immune toxicities. In addition, there is a need for heightened education for both clinicians and patients to enhance understanding and awareness.

Rheumatologic immune checkpoint inhibitor-related adverse events

Rheumatic immune-related adverse events induced by immune checkpoint inhibitors

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

[Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)]

Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update

Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists

Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events

Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach

Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article

Mucocutaneous adverse events to immune checkpoint inhibitors

From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events

Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy

Acknowledging and addressing real-world challenges to treating immune-related adverse events

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors

Toxicity in the era of immune checkpoint inhibitor therapy